Johnson & Johnson

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? (öffnet in neuem Tab)

  The Motley Fool · 01.10.2026

• Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale (öffnet in neuem Tab)

  Currently.com · 01.10.2026

• Johnson & Johnson (NYSE:JNJ) Raises Its Payout (öffnet in neuem Tab)

  Kalkine Media · 01.10.2026

• Johnson & Johnson survey finds women not connecting menopause to eye health changes (öffnet in neuem Tab)

  Fierce Pharma · 01.10.2026

• History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. (öffnet in neuem Tab)

  The Motley Fool · 01.10.2026

• New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause (öffnet in neuem Tab)

  Business Wire · 01.10.2026

• New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause (öffnet in neuem Tab)

  Financial Times · 01.10.2026

• 5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) (öffnet in neuem Tab)

  24/7 Wall St. · 01.10.2026

• ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (öffnet in neuem Tab)

  Zacks · 01.10.2026

• Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow (öffnet in neuem Tab)

  Simply Wall Street · 01.10.2026

• What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing? (öffnet in neuem Tab)

  Insider Monkey · 01.10.2026

• 3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High (öffnet in neuem Tab)

  The Motley Fool · 30.09.2026

• Was The Run In JNJ Stock Hiding In Plain Sight? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years? (öffnet in neuem Tab)

  TIKR.com · 30.09.2026

• Are You Overpaying For Pfizer Stock Versus Its Rivals? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• What Is Merck Stock's Biggest Opportunity? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (öffnet in neuem Tab)

  24/7 Wall St. · 30.09.2026

• SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. (öffnet in neuem Tab)

  Motley Fool · 30.09.2026

• Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Acc (öffnet in neuem Tab)

  Benzinga · 30.09.2026

• What Does Johnson & Johnson (JNJ) Long Term IMAAVY Data Mean For gMG? (öffnet in neuem Tab)

  Simply Wall Street · 30.09.2026

• Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data (öffnet in neuem Tab)

  Simply Wall St. · 30.09.2026

• Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• Do You Really Understand ISRG Stock's Risk? (öffnet in neuem Tab)

  Trefis · 29.09.2026

• Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss (öffnet in neuem Tab)

  Insider Monkey · 29.09.2026

• Defensive Dividends: 3 Companies Investors Can Rely On (öffnet in neuem Tab)

  Zacks · 29.09.2026

• Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (öffnet in neuem Tab)

  Trefis · 29.09.2026

• Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says (öffnet in neuem Tab)

  Proactive · 29.09.2026

• Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss (öffnet in neuem Tab)

  Benzinga · 29.09.2026

• Johnson & Johnson Reports IMAAVY Myasthenia Gravis Data (öffnet in neuem Tab)

  grafa.com · 29.09.2026